Ana Khusnul Faizah, - and Winariani, - and Yulistiani, - and Samirah, - (2015) Procalcitonin as biomarker of antibiotic effectivity in communityacquired pneumonia. Folia Medica Indonesiana, 51 (2). pp. 96-100. ISSN 2599-056X

	Text (FULLTEXT) Bukti C-16 Artikel.pdf Download (2MB)
	Text (KUALITAS KARIL) Bukti C-16 Kualitas Karil.pdf Download (231kB)
	Text (SIMILARITY) Bukti C-16 Turnitin.pdf Download (1MB)

Abstract

Major therapy for community-acquired pneumonia (CAP) is antibiotics. Procalcitonin used as the measure of antibioticseffectiveness. Procalcitonin is specific biomarker that elevates in acute bacterial infection. This study aimed to analyze procalcitoninas effective antibiotics biomarker in CAP patients hospitalized at Pulmonology Department Dr. Soetomo Teaching Hospital. Thisstudy was performed by cohort prospective data and analyzed by descriptively. Data were assessed at before antibiotics, day 3 andday 5 after antibiotics therapy. Nineteen community-acquired pneumonia were enrolled. Serum procalcitonin before antibiotictherapy , day 3 and day 5 antibiotics therapy in CAP are 0.51+ 0.19 (0.28-0.89) ng/ml, 0.53+ 0.24 (0.08-0.93) ng/ml and 0.43+ 0.24(0.00-0.83) ng/ml. Serum procalcitonin in CAP with sepsis patients are 0.51+ 0.19 (0.28-0.89) ng/ml (before antibiotic therapy),0.40 + 0.26 (0.08-0.74) ng/ml (day 3) and 0.22 + 0.13 (0.00-0.32) ng/ml (day 5). Serum Procalcitonin in CAP with pulmonary TBare 0.52 + 0.18 (0.38-0.83) ng/ml, 0.55 + 0.25 (0.23-0.89) ng/ml dan 0.57 + 0.16 (0.41-0.82) ng/ml. Serum procalcitonin in CAPwith sepsis and pulmonary TB are 0.55 + 0.12 (0.38-0.70) ng/ml, 0.56 + 0.15 (0.42-0.73) ng/ml dan 0.47 + 0.15 (0.33-0.64) ng/ml.Procalcitonin of 60% CAP with sepsis patients, 20% CAP with pleural effusion patients and no patients of CAP with pulmonary TBreach <0.26 ng/ml. In conclusion, procalcitonin is not useful biomarker in CAP. (FMI 2015;51:96-100)

Actions (login required)

View Item